  |
|
The ESC guidelines, which are intended to assist health care providers in clinical decision making, now classify FFR-guided treatment as "Class I, with level of evidence A." Level of evidence A is the highest level available, requiring the most clinical evidence, and is awarded only when data has been derived from multiple randomized clinical trials or meta-analyses. Class I indicates a general agreement that a given treatment or procedure is beneficial, useful, and effective. Stefan James, M.D., associate professor of cardiology at Uppsala University Hospital in Uppsala, Sweden, and a member of the ESC Guidelines task force for myocardial revascularization, commented on the update, stating, "The overall aim of the new guidelines for both percutaneous and surgical revascularization has been to shift emphasis from using primarily the anatomical expression of coronary artery disease to guide treatment toward a more patient oriented perspective, where all aspects of the disease are taken into account. In this context, the physiological impact of coronary lesions and FFR-measurements play a central role." Current data show that physiological assessment using FFR prior to placement of coronary stents helps physicians better optimize clinical outcomes by determining which specific lesion or lesions are responsible for a patient's ischemia, a deficiency of blood supply to the heart caused by blood restriction. The recommendations supported by a level of evidence A state that FFR measurements can be useful in assessing whether an intervention in a coronary lesion is necessary, as an alternative to noninvasive functional testing, and to help assess intermediate stenosis in patients with anginal symptoms. "Given the long-term investments St. Jude Medical continues to make in lesion assessment technology, including FFR, we are pleased to see the updated guidelines for this significant technology," said Frank J. Callaghan, president of the St. Jude Medical Cardiovascular Division. "This announcement reinforces the value of FFR as a technology that benefits patients, improves clinical outcomes and reduces the overall cost of treatment." The FAME study was a randomized, prospective, multi-center trial which enrolled 1,005 patients with multivessel coronary artery disease. It compared outcomes for patients whose treatment was guided by FFR to those whose treatment was guided only by angiography. The 12-month results, published in the January 15, 2009 issue of the New England Journal of Medicine, demonstrated that instances of major adverse cardiovascular events (MACE), such as death, myocardial infarction or repeat revascularization, were reduced by 30 percent for patients whose treatment was guided by FFR rather than by standard angiography alone. Two-year results presented as a late-breaking trial during the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference demonstrated that patients who received FFR-guided treatment continued to experience improved outcomes over time, including a 34 percent risk reduction of death or myocardial infarction (heart attack). FFR-guided treatment was also demonstrated to be cost-saving, with a difference of about $2,000, or 14 percent, between total healthcare costs for the FFR-guided cohort and the group treated by angiography alone. These lower healthcare costs were a result of reduced procedural costs, reduced follow-up costs for major adverse cardiac events and shorter hospital stays. St. Jude Medical's FFR Measurement System portfolio includes both the PressureWire Certus and the PressureWire Aeris(TM). The PressureWire Certus was the only FFR Measurement System used in the FAME trial; the PressureWire Aeris is the industry's only wireless technology available, which requires no additional equipment or cabling in the cardiac catheterization laboratory. About Fractional Flow Reserve (FFR) About St. Jude Medical Forward-Looking Statements Source: St. Jude Medical, Inc. |
